Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...

Teva's transformation boosts profit growth and specialty drugs, offering an undervalued opportunity. Click here to read my ...

Teva Pharmaceutical Industries TEVA reported second-quarter 2025 adjusted earnings of 66 cents per share, which beat the ...

Alvotech ALVO, a commercial-stage company developing and manufacturing biosimilar medicines for patients worldwide, is ...

Markets today await the Fed’s rate decision, key GDP data, and earnings from Meta, Microsoft, and Ford in a pivotal U.S.

Deckers Outdoor Corporation (DECK) delivered an impressive first-quarter fiscal 2026 performance, surpassing expectations and increasing year over year. The standout performances of its HOKA and UGG ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the voting results of the Company's annual and special ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Dr. Zuraw led clinical development of telitacicept across MG, Sjögren's, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience ...

TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.

Oklahoma will blend the experience of Dolby and Daniels with talented youth further down the depth chart.

Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company through nine consecutive quarters of growth. On this week’s ...